psoriasis rode schilferende huidziekte
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers must meet the following criteria: • Adults older than 18 years of age • Volunteers must be willing to give a written informed consent • Volunteers must be able to adhere to the visit schedule;Patients must meet the following criteria: • Adults older than 18 years of age • All patients have to have actinic keratosis • The doctor and the patient decided that the best treatment option is field-treatment with imiquimod 5% • Patients must be willing to give a written informed consent • Patients must be able to adhere to the visit schedule
Exclusion criteria
Exclusion criteria: Volunteers will be excluded from this study when any of the following criteria listed below are met: • Children or adolescents younger than 18 years of age • Volunteers with a history or signs of psoriasis • Volunteers with a history or signs of other inflammatory skin diseases, for example atopic dermatitis • Volunteers exposed to large amounts of sunlight or UV-radiation in the last week • Volunteers using immunosuppressive agents like prednisone or methotrexate • Volunteers with relevant co-morbidities • Volunteers with a current condition involving an activated immune system, such as the flue or a recent vaccination;Patients will be excluded from this study when any of the following criteria listed below are met: • Children or adolescents younger than 18 years of age • Patients with a history or signs of psoriasis • Patients with a history or signs of other inflammatory skin diseases, for example atopic dermatitis • Patients exposed to large amounts of sunlight or UV-radiation in the last week • Patients using immunosuppressive agents like prednisone or methotrexate • Patients with relevant co-morbidities • Patients with a current condition involving an activated immune system, such as the flue or a recent vaccination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint will be the presence of IL-17 producing Tregs in the tissues obtained from healthy volunteers (after tape-stripping and LTB4 application) and patients with actinic keratosis treated with imiquimod 5%. Tissues will be analyzed using multicolour immunohistochemistry and immunofleorescence. We developed a sensitive triple staining that is based on the detection of CD4 and Foxp3 expression and IL-17 production. Co-localization of surface differentiation markers, transcription factors and cytokines will be verified by confocal-microscopy. Tissues will be visualized using microscopy, photographed and analysed using computer software (Image J). | — |
Secondary
| Measure | Time frame |
|---|---|
| We will use the mentioned in vivo models for human skin inflammation to analyze the balance of master transcription factors Foxp3 and RORγt through immunohistochemistry and immunofluorescence. We will study co-localization and expression of Foxp3, RORγt and IL-17 by confocal microscopy. | — |
Countries
Netherlands
Outcome results
None listed